New federal vaccination reporting rule may have implications for assisted living
By
Kimberly Bonvissuto
May 12, 2021
A new federal requirement for skilled nursing facilities to report weekly COVID-19 vaccination data may have implications for assisted living providers as efforts to increase vaccination uptake ramp up.
Johns Hopkins doc: COVID-19 to remain public health threat for at least three more months
By
Diane Eastabrook
Apr 01, 2021
The COVID-19 pandemic will continue to be a public health threat for at least three months, according to the chair of Johns Hopkins University’s Emergency Medical Department.
The Equal Employment Opportunity Commission’s May 28 updated and expanded technical guidance regarding the COVID-19 pandemic allows employers to offer incentives to employees to receive a COVID-19...
New state rankings rate pandemic healthcare performance
By
Kathleen Steele Gaivin
Jun 22, 2022
Health systems in Hawaii and Maine ranked the highest among the states as far as vaccination rates, capacity in hospital and intensive care units, and death rates throughout the COVID-19 pandemic, in new...
Bill would ban COVID-19 vaccine mandates despite older adults remaining at highest risk for serious outcomes
By
Kimberly Bonvissuto
Nov 02, 2023
A study underscoring the need to continue to protect older adults from COVID-19 comes as one state appears close to banning COVID-19 vaccine mandates by private employers, including senior living communities.
SARS-CoV-2 vaccine effectiveness 66 percent during delta predominance
Aug 25, 2021
Vaccine effectiveness for all three vaccines decreased from 91% in the months preceding delta predominance.
Biden plan may help mitigate worker shortage for home care providers
By
Diane Eastabrook
May 13, 2021
Home care providers are hopeful a recent move by President Biden could open up the pipeline for available care workers.
Vaccination protects against death from SARS-CoV-2 delta variant
Oct 28, 2021
A Scotland cohort study shows that vaccination effectiveness with the ChAdOx1 nCoV-19 (Astra Zeneca, not available in the U.S.) or BNT162b2 (Pfizer–BioNTech) vaccine was 90% and 87%, respectively, for...
Odds of SARS-CoV-2 infection down after third BNT162b2 dose
Dec 03, 2021
The estimated odds ratio of 0.14 at 28 to 65 days after receipt of the Pfizer-BioNTech booster was compared with those who received two doses.
Third BNT162b2 vaccine dose may cut severe COVID-19 outcomes
Nov 05, 2021
Fewer hospital admissions, cases of severe disease and COVID-19-related deaths were seen with the third dose of the Pfizer-BioNTech vaccine versus two doses received five months ago.